Orange Health Labs
+18%
est. 2Y upside i
India's Fastest Diagnostics Service
Rank
#1665
Sector
Healthcare, Diagnostics, Laboratory Services
Est. Liquidity
~2Y
Data Quality
Data: MediumOrange Health Labs offers strong growth and profitability, but the high preference overhang (46%) significantly dilutes common equity in downside scenarios.
Last updated: July 19, 2026
IPO window opens and strong growth continues; revenue reaches $43.8M by month 24, multiple holds at 10x, yielding 87.6% upside.
Growth slows with decay; revenue $43.8M, multiple compresses to 6x, netting 12.5% upside after preference.
Competitive pressure or macroeconomic headwinds compress multiple to 4x; exit value $175.2M, preference stack reduces common to 68.1M, resulting in -70.8% return.
Preference Stack Risk
severeFunding Intensity
46%$107.1M in preference vs $233.5M valuation, representing 46% overhang.
Dilution Risk
moderateCompany is profitable and just raised $30M, so no immediate dilutive raise expected; future option pool grants could cause ~2-3% annual dilution.
Secondary Liquidity
noneNo secondary market observed; liquidity expected only via IPO or acquisition.
Questions to Ask at the Interview
Strategic questions based on Orange Health Labs's data — designed to show you've done your homework.
- 1
“How will Orange Health expand beyond urban India and maintain rapid collection times?”
- 2
“What are the unit economics and gross margin trends for at-home diagnostics?”
- 3
“How does the preference stack affect employee equity value in an exit scenario?”
Community
Valuation Sentiment
Our model estimates +18% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.